Shopping Cart 0
Cart Subtotal
USD 0

Cell-Division-Cycle-7-Related-Protein-Kinase-(CDC7-or-EC-2.7.11.1)-Pipeline-Review-H2-2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Pipeline Review, H2 2017

Summary

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Pancreatic Cancer, Blood Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Pipeline Review, H2 2017, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Overview

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Companies Involved in Therapeutics Development

Eli Lilly and Company

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Sierra Oncology Inc

Takeda Pharmaceutical Company Ltd

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Drug Profiles

LBS-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143921-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSK-777-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDC7 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC-7 for Pancreatic Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC7 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRA-141-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-931-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Dormant Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Eli Lilly and Company, H2 2017

Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Sierra Oncology Inc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Therapeutic Products under Development, Key Players in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Therapeutics, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline Overview, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline Assessment


Companies

Eli Lilly and Company

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Sierra Oncology Inc

Takeda Pharmaceutical Company Ltd

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Pipeline Review, H2 2017

Summary

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Pancreatic Cancer, Blood Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Pipeline Review, H2 2017, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Overview

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Companies Involved in Therapeutics Development

Eli Lilly and Company

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Sierra Oncology Inc

Takeda Pharmaceutical Company Ltd

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Drug Profiles

LBS-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143921-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSK-777-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDC7 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC-7 for Pancreatic Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDC7 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRA-141-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-931-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Dormant Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Eli Lilly and Company, H2 2017

Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Sierra Oncology Inc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Therapeutic Products under Development, Key Players in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Therapeutics, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline Overview, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline, Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Pipeline Assessment


Companies

Eli Lilly and Company

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Sierra Oncology Inc

Takeda Pharmaceutical Company Ltd